Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 10/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL27578446 | 1.00 | DNM1 (0.46) | DNM1TSHRALDH1A1TP53CYP3A4 | |
| Bromide SCHEMBL28983783 | 1.00 | DNM1 (0.46) | DNM1TSHRALDH1A1TP53CYP3A4 | |
| Bromide SCHEMBL28545117 | 1.00 | DNM1 (0.46) | DNM1TSHRALDH1A1TP53CYP3A4 | |
| Bromide SCHEMBL594635 | 1.00 | DNM1 (0.46) | DNM1TSHRALDH1A1TP53CYP3A4 | |
| Bromide SCHEMBL28730749 | 1.00 | DNM1 (0.46) | DNM1TSHRALDH1A1TP53CYP3A4 | |
| Bromide SCHEMBL28537300 | 1.00 | DNM1 (0.46) | DNM1TSHRALDH1A1TP53CYP3A4 | |
| Bromide SCHEMBL29019024 | 1.00 | DNM1 (0.46) | DNM1TSHRALDH1A1TP53CYP3A4 | |
| Bromide SCHEMBL9482055 | 1.00 | DNM1 (0.46) | DNM1TSHRALDH1A1TP53CYP3A4 | |
| Bromide SCHEMBL21494331 | 1.00 | DNM1 (0.46) | DNM1TSHRALDH1A1TP53CYP3A4 | |
| Bromide SCHEMBL26105712 | 1.00 | DNM1 (0.46) | DNM1TSHRALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528601-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF PULMONARY HYPERTENSION | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2012-12-05 | — | — | EP | claimed |
| WO-2011092690-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF PULMONARY HYPERTENSION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2011-08-04 | — | — | WO | claimed |
| US-20210113580-A1 | NANOPARTICULATE MELOXICAM FORMULATIONS | BAUDAX BIO, INC. | 2021-04-22 | — | — | US | disclosed |
| US-10709713-B2 | Nanoparticulate meloxicam formulations | BAUDAX BIO, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200155564-A1 | Nanoparticulate Meloxicam Formulations | RECRO TECHNOLOGY LLC | 2020-05-21 | — | — | US | disclosed |
| US-10471067-B2 | Nanoparticulate meloxicam formulations | RECRO PHARMA, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10463673-B2 | Nanoparticulate meloxicam formulations | RECRO PHARMA, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20170157061-A1 | Nanoparticulate Meloxicam Formulations | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-06-08 | — | — | US | disclosed |
| US-20150283092-A1 | DRUG DELIVERY COMPOSITION | ALKERMES PHARMA IRELAND LTD (IE) | 2015-10-08 | — | — | US | disclosed |
| US-20140141083-A1 | NANOPARTICULATE MELOXICAM FORMULATIONS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2014-05-22 | — | — | US | disclosed |
| US-20130102591-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF PULMONARY HYPERTENSION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2013-04-25 | — | — | US | disclosed |
| WO-2008118754-A2 | GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHODS FOR MAKING THE SAME | ELAN CORPORATION PLC (IE) | 2008-10-02 | — | — | WO | disclosed |
| US-20080220074-A1 | GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHODS OF MAKING SAME | ELAN CORPORATION PLC (IE) | 2008-09-11 | — | — | US | disclosed |
| US-20070122486-A1 | Nanoparticulate insulin | ELAN PHARMA INTERNATIONAL LIMITED | 2007-05-31 | — | — | US | disclosed |
| EP-1429731-B1 | NANOPARTICULATE INSULIN FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2007-01-03 | — | — | EP | disclosed |
| EP-1429731-A1 | NANOPARTICULATE INSULIN FORMULATIONS | Elan Pharma International Limited (IE) | 2004-06-23 | — | — | EP | disclosed |
| US-20030095928-A1 | Nanoparticulate insulin | ELAN PHARMA INTERNATIONAL LIMITED | 2003-05-22 | — | — | US | disclosed |
| WO-2003024425-A1 | NANOPARTICULATE INSULIN FORMULATIONS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-03-27 | — | — | WO | disclosed |
| EP-0533869-A1 | NEMATICIDAL PYRIMDINE DERIVATIVES | ZENECA LIMITED (GB) | 1993-03-31 | — | — | EP | disclosed |
| WO-1992017459-A1 | NEMATICIDAL PYRIMDINE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102591-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF PULMONARY HYPERTENSION | NOS3, NOS2, NOS1 | OPRM1 1522/4885DNM1 369/4885TSHR 4024/4885 |
| US-20170157061-A1 | Nanoparticulate Meloxicam Formulations | MTNR1A, MB, MTDH | OPRM1 110/4885DNM1 3368/4885TSHR 1724/4885 |
| US-10463673-B2 | Nanoparticulate meloxicam formulations | MTNR1A, MB, MTDH | OPRM1 110/4885DNM1 3368/4885TSHR 1724/4885 |
| US-20200155564-A1 | Nanoparticulate Meloxicam Formulations | MTNR1A, MB, MTDH | OPRM1 110/4885DNM1 3368/4885TSHR 1724/4885 |
| US-10709713-B2 | Nanoparticulate meloxicam formulations | MTNR1A, MB, MTDH | OPRM1 110/4885DNM1 3368/4885TSHR 1724/4885 |
| US-10471067-B2 | Nanoparticulate meloxicam formulations | MTNR1A, MB, MTDH | OPRM1 110/4885DNM1 3368/4885TSHR 1724/4885 |
| US-20210113580-A1 | NANOPARTICULATE MELOXICAM FORMULATIONS | MTNR1A, MB, MTDH | OPRM1 110/4885DNM1 3368/4885TSHR 1724/4885 |
| US-20140141083-A1 | NANOPARTICULATE MELOXICAM FORMULATIONS | MTNR1A, MB, MTDH | OPRM1 110/4885DNM1 3368/4885TSHR 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.